People: Acasti Pharma Inc (ACST.OQ)

ACST.OQ on NASDAQ Stock Exchange Capital Market

0.31USD
7 Jul 2015
Change (% chg)

$-0.01 (-2.18%)
Prev Close
$0.32
Open
$0.31
Day's High
$0.34
Day's Low
$0.31
Volume
68,256
Avg. Vol
19,825
52-wk High
$1.22
52-wk Low
$0.29

Search Stocks

Summary

Name Age Since Current Position

Jerald Wenker

2014 Independent Chairman of the Board

Pierre Lemieux

2010 Chief Operating Officer

Laurent Harvey

Vice President- Clinical and Non-Clinical Affairs

Jean -Daniel Belanger

Secretary, Director- Corporate Affairs

Harlan Waksal

61 2014 Director

Valier Boivin

2013 Independent Director

Jean-Claude Debard

2013 Independent Director

Ronald Denis

2014 Director

Pierre Fitzgibbon

60 2014 Independent Director

Adrian Montgomery

2014 Independent Director

Reed Tuckson

64 2013 Independent Director

Biographies

Name Description

Jerald Wenker

Mr. Jerald J. Wenker serves as a Independent Chairman of the Board of Acasti Pharma Inc., Mr. Wenker is currently President and Chief Operating Officer of Dermalogica, a leading professional skin care company based in the United States. Previously, he was President of Ther-Rx Corporation, the branded division of KV Pharmaceuticals. Prior to Ther-Rx, Mr. Wenker worked at Abbott Laboratories for approximately 15 years where he held several executive roles in such areas as commercial and marketing management, strategic planning, licensing and new business development as well as new product development. Mr. Wenker holds a Master of Science in Marketing and MBA from Northwestern University’s J.L. Kellogg Graduate School of Management.

Pierre Lemieux

Dr. Pierre Lemieux Ph.D. serves as the Chief Operating Officer of Acasti Pharma Inc., Dr. Pierre Lemieux has been the Chief Operating Officer of the Corporation since April 12, 2010. He holds a post-doctoral degree in Oncology from the Health Science Center, University of Texas (San Antonio), United States, and a PhD in biochemistry from Laval University, Canada, jointly with University of Nottingham, England. Prior to joining the Corporation, Dr. Lemieux was the President, Chief Executive Officer and the chairman of the board as well as being the founder of Technologie Biolactis Inc., a late-stage biotechnology company specialized in the valorization of proteins to better serve the nutraceutical, cosmetic and pharmaceutical industries.

Laurent Harvey

Mr. Laurent Harvey serves as the Vice President, Clinical and Non-Clinical Affairs of the company. Laurent has more than 25 years’ experience in the biopharmaceutical industry, primarily in drug development and clinical research. Before joining Acasti Pharma, he occupied different management positions at Bristol-Myers Squibb, Æterna-Zentaris, Innodia, Bellus Health and KLOX Technologies. During his career, he participated in many national and international clinical programs in various therapeutic fields such as cardiovascular, endocrinology, oncology and neurology. Laurent holds a Bachelor’s degree in pharmacy and M.Sc in hospital pharmacy, both from Université de Montréal.

Jean -Daniel Belanger

Mr. Jean-Daniel Belanger serves as the Corporate Secretary and Director, Corporate Affairs of the company. Mr. Bélanger is Director Corporate Affairs of the Corporation since November 2012 and Corporate Secretary since June 2014. He is in charge of all corporate, governance and securities law matters of the Corporation. He oversees and leads negotiations on corporate and financing matters and is an integral member of the management team, reporting directly to the President and Chief Executive Officer. He holds a law degree from the Université de Montréal (2005) and is a member of the Quebec Bar since 2006. Prior to joining the Corporation, Jean-Daniel was a partner in a Montreal securities boutique-firm, where he practiced in the areas of mergers and acquisitions, corporate finance and securities, and general corporate and commercial law.

Harlan Waksal

Dr. Harlan W. Waksal, M.D., serves as the Director of Acasti Pharma Inc., Dr. Harlan W. Waksal is a retired physician. Dr. Waksal is the Vice-President, Business and Scientific Affairs at Acasti. He received his B.A. from Oberlin College and M.D. from Tufts University School of Medicine, and his post graduate training in Internal Medicine and in Pathology. In addition, he did research in immunology at the Weizmann Institute of Science. Dr. Waksal was a founder of Imclone Systems Incorporated; a New York based pharmaceutical company specializing in developing new treatment for various forms of cancer. He served as the Chief Operating Officer and member of the Board of Directors from 1986 until 2001 and as President/CEO from 2001 until 2002. During his tenure, he was responsible for building the scientific and operation infrastructure of the company. Dr. Waksal is the author of over 50 scientific publications and has been the author of multiple patents and patent applications. His current activities are focused on managing various real estate developments and serving on select Board of Directors. Dr. Waksal currently serves on the Boards of the Oberlin College, Senesco Technologies, Inc. He also serves on the Advisory Board of Northern Rivers Funds.

Valier Boivin

Mr. Valier Boivin serves as an Independent Director of Acasti Pharma Inc., Mr. Valier Boivin holds a bachelor’s degree in Economic and Administrative Sciences (UQAC-1973), a master’s degree in Taxation (Université de Sherbrooke, 1978) and a law degree (Université de Montréal, 1985). He has also been a member of the “Barreau du Québec” since 1986 and the “Ordre des comptables agréés du Québec” since 1974. He held the position of Professor at the Université du Québec à Chicoutimi until 1978 and then joined the master’s degree in taxation program as Professor at the Université de Sherbrooke until 1987. Founder (in 1987) of Boivin O’Neil, s.e.n.c., he also practices business law. Specialized in mergers & acquisitions and corporate financing, he acts as legal and strategic counsel to many private and public companies. Since January 2009, he has occupied the position of President of the regional economic intervention fund, FIER Ville-Marie, L.P. Mr. Boivin is also socially involved with various professional associations, non-profit organizations and charitable foundations.

Jean-Claude Debard

Mr. Jean-Claude Debard serves as an Independent Director of Acasti Pharma Inc., Mr. Jean-Claude Debard has been President of M Motors Automobiles France, Subaru France, Daihatsu France, SsangYong France since 2012 and FEA Services as well as an officer of Frey Accessories and Parts since 1999 and most recently Executive President of Group Emil Frey France since 2008. Since 1999, Mr. Debard has served on the Oversight Committee of Holding (SERGESA), SsangYong France and Hyundai Finances. Mr. Debard also has a graduate degree in Management and Strategic Management.

Ronald Denis

Dr. Ronald Denis serves as an Independent Director of Acasti Pharma Inc. Dr. Ronald Denis has been Chief of Surgery and director of the Trauma Program at Hôpital du Sacré-Coeur in Montréal since 1997. Since 1987, Dr. Denis has also been medical co-director of the Canadian Formula 1 Grand Prix. Dr. Denis sits on several scientific boards and management committees.

Pierre Fitzgibbon

Mr. Pierre Fitzgibbon serves as the Independent Director of the comapny. Mr. Fitzgibbon was the President and Chief Executive Officer of Atrium Innovations Inc., a leader in the development, manufacturing and marketing of added value products for the health and nutrition industry, which was recently sold to corporations backed by the Permira funds in a transaction valued at over $1.1 billion. Prior to joining Atrium Innovations, Mr. Fitzgibbon was Vice-Chairman of National Bank Financial and Senior Vice-President, Finance, Technology and Corporate Affairs at National Bank of Canada. He holds a bachelor’s degree in business administration from the École des hautes études commerciales of Montreal and a certificate in general management from Harvard Business School. Mr. Fitzgibbon currently serves on the board of directors of other corporations.

Adrian Montgomery

Mr. Adrian T. Montgomery serves as the Independent Director of the company. Mr. Montgomery is the President of Tuckamore Capital, a publicly-traded company that has invested approximately $700 million in successful private businesses since its inception in 2005. Prior to joining Tuckamore, he headed business development at Rogers Media Inc. Mr. Montgomery is a lawyer and member of the New York State Bar and currently serves on the boards of Epsilon Energy, a TSX-listed Company, and the Toronto East General Hospital Foundation.

Reed Tuckson

Dr. Reed V. Tuckson, M.D., serves as an Independent Director of Acasti Pharma Inc., with effect from 5 November 2013. Dr. Tuckson is currently the managing director of Tuckson Health Connections LLC, a health and medical care consulting business. Previously, he served a long tenure as executive vice-president and chief of medical affairs for UnitedHealth Group, a Fortune 25 health and well-being company, which includes the United States' largest health insurer and the industry's most comprehensive health services company. Among his many committee memberships, Dr. Tuckson is member of the advisory committee to the director of the National Institutes of Health and is also an active member of the Institute of Medicine of the National Academy of Sciences. He also serves on the boards of the American Telemedicine Association, Howard University and Cell Therapeutics Inc., a public corporation. Dr. Tuckson has been noted several times by Modern Healthcare Magazine as one of the 50 most powerful physician executives in health care and Black Enterprise Magazine featured him as one of the most powerful executives in corporate America. Dr. Tuckson is a graduate of Howard University, Georgetown University's school of medicine, and the hospital of the University of Pennsylvania's general internal medicine residency and fellowship programs, where he was also a Robert Wood Johnson Foundation clinical scholar studying at the Wharton School of Business.

Basic Compensation

Search Stocks